論文

国際誌
2019年10月24日

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.

BMC cancer
  • Kenji Omae
  • ,
  • Yuki Kataoka
  • ,
  • Yasushi Tsujimoto
  • ,
  • Yusuke Tsutsumi
  • ,
  • Yosuke Yamamoto
  • ,
  • Shunichi Fukuhara
  • ,
  • Toshi A Furukawa

19
1
開始ページ
998
終了ページ
998
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1186/s12885-019-6232-x

BACKGROUND: The low data publication rate for Food and Drug Administration (FDA)-approved drugs, and discrepancies between FDA-submitted versus published data, remain a concern. We investigated the publication statuses of sponsor-submitted clinical trials supporting recent anticancer drugs approved by the FDA, with a focus on immune checkpoint inhibitors (ICPis). METHODS: We identified all ICPis approved between 2011 and 2014, thereby obtaining 3 years of follow-up data. We assessed the clinical trials performed for each drug indication and matched each trial with publications in the literature. The primary benchmark was the publication status 2 years post-approval. We examined the association between time to publication and drug type using a multilevel Cox regression model that was adjusted for clustering within drug indications and individual covariates. RESULTS: Between 2011 and 2014, 36 anticancer drugs including 3 ICPis were newly approved by the FDA. Of 19 trials investigating the 3 ICPis, 11 (58%) were published within 2 years post-approval. We randomly selected 10 of the 33 remaining anticancer drugs; 68 of 101 trials investigating these drugs (67%) were published. Overall, the publication rate was 66% at 2 years post-approval with a median time to publication of 2.3 years. There was no significant difference in the time to trial publication between ICPis and other anticancer drugs (adjusted hazard ratio [HR], 1.1; 95% confidence interval [CI], 0.8-1.7; P = 0.55). However, findings related to non-ICPis investigated specifically in randomized phase 2 or phase 3 trials were significantly more likely to be published earlier than those related to ICPis (adjusted HR, 7.4; 95% CI, 1.8-29.5; P = 0.005). CONCLUSION: One in 3 sponsor-submitted trials of the most recently approved anticancer drugs remained unpublished 2 years post-FDA approval. We found no evidence that the drug type was associated with the time to overall trial publication.

リンク情報
DOI
https://doi.org/10.1186/s12885-019-6232-x
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31651263
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814120

エクスポート
BibTeX RIS